miR-22 inhibits the proliferation, motility, and invasion of human glioblastoma cells by directly targeting SIRT1

Recently, microRNAs (miRNAs), a kind of small and non-coding RNA, can target the downstream molecules. Increasing evidence demonstrates that miRNAs meditate the onset and progression of a variety of tumors. In the present study, we carried out gene transfection, western blot, and reverse transcripti...

Full description

Saved in:
Bibliographic Details
Published inTumor biology Vol. 37; no. 5; pp. 6761 - 6768
Main Authors Chen, Hanchun, Lu, Qiong, Fei, Xifeng, Shen, Likui, Jiang, Dongyi, Dai, Dongwei
Format Journal Article
LanguageEnglish
Published Dordrecht Springer Netherlands 01.05.2016
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Recently, microRNAs (miRNAs), a kind of small and non-coding RNA, can target the downstream molecules. Increasing evidence demonstrates that miRNAs meditate the onset and progression of a variety of tumors. In the present study, we carried out gene transfection, western blot, and reverse transcription PCR (RT-PCR) to explore the role of miR-22 in glioblastoma tissues and cell lines. Here, we verified that the expression of miR-22 was downregulated in glioblastoma tissues and cells rather than matched non-tumor tissues and normal human astrocyte (NHA) cells ( p  < 0.001). By contrast, SIRT1 messenger RNA (mRNA) and protein were upregulated in glioblastoma tissues and cells ( p  < 0.001). In vitro miR-22 mimics interfered with cell proliferation, migration, and invasion of U87 and U251 cells. Mechanically, the 3′-untranslated regions (3′-UTRs) of SIRT1 were a direct target of miR-22, leading to the decreased expression of SIRT1 protein in U87 and U251 cells. Meanwhile, miR-22 mimics also inhibited the expression of epidermal growth factor receptor (EGFR) and matrix metallopeptidase 9 (MMP9). In conclusion, miR-22 inhibited cell proliferation, migration, and invasion via targeting the 3′-UTR of SIRT1 in the progression of glioblastoma and miR-22-SIRT1 pathway can be recommended as a potential target for treatment of glioblastoma.
AbstractList Recently, microRNAs (miRNAs), a kind of small and non-coding RNA, can target the downstream molecules. Increasing evidence demonstrates that miRNAs meditate the onset and progression of a variety of tumors. In the present study, we carried out gene transfection, western blot, and reverse transcription PCR (RT-PCR) to explore the role of miR-22 in glioblastoma tissues and cell lines. Here, we verified that the expression of miR-22 was downregulated in glioblastoma tissues and cells rather than matched non-tumor tissues and normal human astrocyte (NHA) cells (p < 0.001). By contrast, SIRT1 messenger RNA (mRNA) and protein were upregulated in glioblastoma tissues and cells (p < 0.001). In vitro miR-22 mimics interfered with cell proliferation, migration, and invasion of U87 and U251 cells. Mechanically, the 3'-untranslated regions (3'-UTRs) of SIRT1 were a direct target of miR-22, leading to the decreased expression of SIRT1 protein in U87 and U251 cells. Meanwhile, miR-22 mimics also inhibited the expression of epidermal growth factor receptor (EGFR) and matrix metallopeptidase 9 (MMP9). In conclusion, miR-22 inhibited cell proliferation, migration, and invasion via targeting the 3'-UTR of SIRT1 in the progression of glioblastoma and miR-22-SIRT1 pathway can be recommended as a potential target for treatment of glioblastoma.Recently, microRNAs (miRNAs), a kind of small and non-coding RNA, can target the downstream molecules. Increasing evidence demonstrates that miRNAs meditate the onset and progression of a variety of tumors. In the present study, we carried out gene transfection, western blot, and reverse transcription PCR (RT-PCR) to explore the role of miR-22 in glioblastoma tissues and cell lines. Here, we verified that the expression of miR-22 was downregulated in glioblastoma tissues and cells rather than matched non-tumor tissues and normal human astrocyte (NHA) cells (p < 0.001). By contrast, SIRT1 messenger RNA (mRNA) and protein were upregulated in glioblastoma tissues and cells (p < 0.001). In vitro miR-22 mimics interfered with cell proliferation, migration, and invasion of U87 and U251 cells. Mechanically, the 3'-untranslated regions (3'-UTRs) of SIRT1 were a direct target of miR-22, leading to the decreased expression of SIRT1 protein in U87 and U251 cells. Meanwhile, miR-22 mimics also inhibited the expression of epidermal growth factor receptor (EGFR) and matrix metallopeptidase 9 (MMP9). In conclusion, miR-22 inhibited cell proliferation, migration, and invasion via targeting the 3'-UTR of SIRT1 in the progression of glioblastoma and miR-22-SIRT1 pathway can be recommended as a potential target for treatment of glioblastoma.
Recently, microRNAs (miRNAs), a kind of small and non-coding RNA, can target the downstream molecules. Increasing evidence demonstrates that miRNAs meditate the onset and progression of a variety of tumors. In the present study, we carried out gene transfection, western blot, and reverse transcription PCR (RT-PCR) to explore the role of miR-22 in glioblastoma tissues and cell lines. Here, we verified that the expression of miR-22 was downregulated in glioblastoma tissues and cells rather than matched non-tumor tissues and normal human astrocyte (NHA) cells ( p  < 0.001). By contrast, SIRT1 messenger RNA (mRNA) and protein were upregulated in glioblastoma tissues and cells ( p  < 0.001). In vitro miR-22 mimics interfered with cell proliferation, migration, and invasion of U87 and U251 cells. Mechanically, the 3′-untranslated regions (3′-UTRs) of SIRT1 were a direct target of miR-22, leading to the decreased expression of SIRT1 protein in U87 and U251 cells. Meanwhile, miR-22 mimics also inhibited the expression of epidermal growth factor receptor (EGFR) and matrix metallopeptidase 9 (MMP9). In conclusion, miR-22 inhibited cell proliferation, migration, and invasion via targeting the 3′-UTR of SIRT1 in the progression of glioblastoma and miR-22-SIRT1 pathway can be recommended as a potential target for treatment of glioblastoma.
Recently, microRNAs (miRNAs), a kind of small and non-coding RNA, can target the downstream molecules. Increasing evidence demonstrates that miRNAs meditate the onset and progression of a variety of tumors. In the present study, we carried out gene transfection, western blot, and reverse transcription PCR (RT-PCR) to explore the role of miR-22 in glioblastoma tissues and cell lines. Here, we verified that the expression of miR-22 was downregulated in glioblastoma tissues and cells rather than matched non-tumor tissues and normal human astrocyte (NHA) cells (p < 0.001). By contrast, SIRT1 messenger RNA (mRNA) and protein were upregulated in glioblastoma tissues and cells (p < 0.001). In vitro miR-22 mimics interfered with cell proliferation, migration, and invasion of U87 and U251 cells. Mechanically, the 3'-untranslated regions (3'-UTRs) of SIRT1 were a direct target of miR-22, leading to the decreased expression of SIRT1 protein in U87 and U251 cells. Meanwhile, miR-22 mimics also inhibited the expression of epidermal growth factor receptor (EGFR) and matrix metallopeptidase 9 (MMP9). In conclusion, miR-22 inhibited cell proliferation, migration, and invasion via targeting the 3'-UTR of SIRT1 in the progression of glioblastoma and miR-22-SIRT1 pathway can be recommended as a potential target for treatment of glioblastoma.
Author Chen, Hanchun
Shen, Likui
Jiang, Dongyi
Lu, Qiong
Fei, Xifeng
Dai, Dongwei
Author_xml – sequence: 1
  givenname: Hanchun
  surname: Chen
  fullname: Chen, Hanchun
  organization: Department of Neurosurgery, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine
– sequence: 2
  givenname: Qiong
  surname: Lu
  fullname: Lu, Qiong
  organization: Department of Laboratory Medicine, Changhai Hospital, Second Military Medical University
– sequence: 3
  givenname: Xifeng
  surname: Fei
  fullname: Fei, Xifeng
  organization: Department of Neurosurgery, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine
– sequence: 4
  givenname: Likui
  surname: Shen
  fullname: Shen, Likui
  organization: Department of Neurosurgery, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine
– sequence: 5
  givenname: Dongyi
  surname: Jiang
  fullname: Jiang, Dongyi
  organization: Department of Neurosurgery, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine
– sequence: 6
  givenname: Dongwei
  surname: Dai
  fullname: Dai, Dongwei
  email: daidwshanghai@163.com
  organization: Department of Neurosurgery, Changhai Hospital, Second Military Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26662303$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1rHSEYhaWkNB_tD-gmCN10EVu_xnGWJTQfECik6VocR-81OJqoE7j_Pt7cBEIgXSn6nMN533MI9mKKFoCvBP8gGPc_C2G07xEmHeJd3yH5ARwQThnCTOK9dscEI04l2weHpdziBg6D-AT2qRCCMswOwP3srxGl0Me1H30tsK4tvMspeGezrj7FEzin6oOvmxOo49TIB13aO0wOrpdZR7gKPo1Bl5pmDY0NocBxAyefralhA6vOK1t9XMG_l9c35DP46HQo9svzeQT-nf2-Ob1AV3_OL09_XSHDmaxIS9OxkTtBhRGCODYxTHpOOqe7gVDCjaTtU3PGxDQSYaRz1GKrnZ20NpYdge873zbN_WJLVbMv23Q62rQURfoBcyGpFA399ga9TUuOLd0TRTo20KFRx8_UMs52UnfZzzpv1MsyG9DvAJNTKdk6ZXx92mHN2gdFsNrWpna1qeartrUp2ZTkjfLF_H8autOUxsaVza9Cvyt6BCYbqUY
CitedBy_id crossref_primary_10_1002_biot_201700342
crossref_primary_10_3389_fcell_2017_00043
crossref_primary_10_1016_j_ijbiomac_2019_02_012
crossref_primary_10_1016_j_ijbiomac_2021_08_013
crossref_primary_10_1016_j_bbadva_2023_100078
crossref_primary_10_3390_ijms23169272
crossref_primary_10_1371_journal_pone_0168412
crossref_primary_10_1007_s12015_019_09924_0
crossref_primary_10_1042_BSR20170695
crossref_primary_10_1016_j_cbi_2022_110224
crossref_primary_10_1016_j_biopha_2017_05_074
crossref_primary_10_1289_EHP8314
crossref_primary_10_1038_s41420_021_00734_3
crossref_primary_10_3892_etm_2021_9669
crossref_primary_10_1016_j_yexmp_2020_104550
crossref_primary_10_1155_2016_1279051
crossref_primary_10_1016_j_biopha_2020_111115
crossref_primary_10_3389_fmedt_2021_678593
crossref_primary_10_1248_bpb_b18_00084
crossref_primary_10_1016_j_heliyon_2022_e10384
crossref_primary_10_1038_s41388_022_02236_7
crossref_primary_10_1002_1873_3468_12565
crossref_primary_10_1007_s12035_022_02769_8
crossref_primary_10_1038_s41598_018_26547_6
crossref_primary_10_1038_s41417_025_00880_1
crossref_primary_10_3390_nu14224901
crossref_primary_10_3892_mmr_2017_7481
crossref_primary_10_1038_s41467_018_04600_2
crossref_primary_10_1038_s41598_020_61734_4
crossref_primary_10_1016_j_biopha_2023_116029
crossref_primary_10_3390_ijms24076392
crossref_primary_10_3892_ol_2019_10235
crossref_primary_10_1186_s12985_017_0743_3
crossref_primary_10_18632_oncotarget_12395
crossref_primary_10_3390_ijms242216320
crossref_primary_10_3171_2016_8_SPINE16248
crossref_primary_10_20517_cdr_2024_157
crossref_primary_10_1007_s11481_024_10101_5
crossref_primary_10_3389_fnmol_2018_00339
crossref_primary_10_1016_j_bbrc_2016_08_133
crossref_primary_10_1111_1755_5922_12318
crossref_primary_10_1111_jcmm_18288
crossref_primary_10_1002_jcb_27966
crossref_primary_10_1016_j_molmet_2020_101087
crossref_primary_10_1186_s40659_017_0133_8
crossref_primary_10_1002_biof_1604
crossref_primary_10_3389_fphar_2019_00451
crossref_primary_10_1038_s41419_019_1373_z
crossref_primary_10_17816_MAJ83594
Cites_doi 10.1016/j.cell.2010.03.015
10.3233/CBM-150465
10.3748/wjg.v21.i34.9838
10.1158/0008-5472.CAN-09-2918
10.1111/j.1742-4658.2010.07594.x
10.3389/fped.2015.00069
10.1007/s12035-014-8850-2
10.3390/jcm4091741
10.1038/nature03315
10.1007/s12032-015-0706-8
10.1016/j.pbi.2015.07.008
10.1038/ni.3292
10.3322/caac.20073
10.1016/j.jval.2015.09.1122
10.1007/s12035-014-8935-y
10.1186/s13578-015-0055-5
10.1007/s12035-015-9340-x
10.3892/or.2015.4167
10.1007/s12035-015-9121-6
10.1007/s12035-015-9525-3
10.1177/172460080001500305
10.1186/1479-5876-12-54
10.1007/s12035-014-9006-0
ContentType Journal Article
Copyright International Society of Oncology and BioMarkers (ISOBM) 2015
International Society of Oncology and BioMarkers (ISOBM) 2016
Copyright_xml – notice: International Society of Oncology and BioMarkers (ISOBM) 2015
– notice: International Society of Oncology and BioMarkers (ISOBM) 2016
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TO
H94
K9.
7X8
DOI 10.1007/s13277-015-4575-8
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
EISSN 1423-0380
EndPage 6768
ExternalDocumentID 4062894441
26662303
10_1007_s13277_015_4575_8
Genre Journal Article
Feature
GroupedDBID ---
.GJ
06D
0VX
0VY
0~B
123
1N0
203
29Q
29~
2KM
2LR
2VQ
30V
30W
328
36B
3V.
4.4
408
40D
53G
67N
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8UI
8UJ
96X
AAIAL
AAJKR
AARHV
AARTL
AASGM
AAWCG
AAYIC
AAYIU
AAYQN
AAYTO
AAYZH
AAZMS
ABBTS
ABJOX
ABPLI
ABQXT
ABTEG
ABTHY
ABTMW
ABUWG
ABWCG
ACBXY
ACGFS
ACKNC
ACPQW
ACPRK
ACQXL
ADAGL
ADBBV
ADHIR
ADINQ
ADKPE
ADZMO
AEGNC
AEJHL
AENEX
AEOHA
AEPYU
AETCA
AEWDL
AEYAO
AFBBN
AFCOW
AFDXO
AFKRA
AFKRG
AFLOW
AFRWT
AFSIO
AFWTZ
AFZKB
AGAYW
AGJBK
AGQMX
AGWZB
AGYKE
AHAVH
AHBYD
AHMBA
AHSBF
AHYZX
AIIXL
AIOMO
AJBLW
AJUZI
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
ANMIH
AUTPY
AYAKG
AZQEC
BBNVY
BCNDV
BDDNI
BENPR
BGNMA
BHPHI
BPHCQ
BSEHC
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
CYUIP
DU5
DV7
DWQXO
E0A
EBD
EBS
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FB.
FRRFC
FYJPI
FYUFA
GGRSB
GNUQQ
GQ6
GQ7
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
GUQSH
H13
HCIFZ
HF~
HMCUK
HMJXF
HRMNR
HZ~
IOS
ITM
J0Z
J8X
JBSCW
K.F
KOV
LK8
M1P
M2O
M4Y
M7P
N9A
NQS
NU0
O1H
O9-
O93
O9I
OK1
PADUT
PIMPY
PQQKQ
PROAC
PSQYO
Q2X
R9I
RIG
RKO
ROL
RSV
RXVBD
S1Z
S27
S3A
S3B
SAUOL
SBL
SFC
SHX
SOJ
SV3
T13
U2A
U9L
UDS
UG4
UJ6
UKHRP
VC2
W48
WK8
Z45
ZOVNA
ZXP
~A9
0R~
AAYXX
ABFSG
ACHEB
ACSTC
AEZWR
AFHIU
AHWEU
AIXLP
CITATION
PHGZM
PHGZT
SCNPE
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TO
H94
K9.
7X8
ID FETCH-LOGICAL-c438t-a8c53b4f626c661f3d3017415fa591214c82f62a4336db16c8ff2e0eafedaace3
IEDL.DBID U2A
ISSN 1010-4283
1423-0380
IngestDate Fri Jul 11 13:05:58 EDT 2025
Sat Aug 23 12:57:52 EDT 2025
Wed Feb 19 01:59:36 EST 2025
Tue Jul 01 02:37:32 EDT 2025
Thu Apr 24 23:03:23 EDT 2025
Fri Feb 21 02:38:29 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords SIRT1
miR-22
Glioblastoma
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c438t-a8c53b4f626c661f3d3017415fa591214c82f62a4336db16c8ff2e0eafedaace3
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
PMID 26662303
PQID 1790153929
PQPubID 33651
PageCount 8
ParticipantIDs proquest_miscellaneous_1790468286
proquest_journals_1790153929
pubmed_primary_26662303
crossref_citationtrail_10_1007_s13277_015_4575_8
crossref_primary_10_1007_s13277_015_4575_8
springer_journals_10_1007_s13277_015_4575_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-05-01
PublicationDateYYYYMMDD 2016-05-01
PublicationDate_xml – month: 05
  year: 2016
  text: 2016-05-01
  day: 01
PublicationDecade 2010
PublicationPlace Dordrecht
PublicationPlace_xml – name: Dordrecht
– name: United States
– name: London
PublicationSubtitle Tumor Markers, Tumor Targeting and Translational Cancer Research
PublicationTitle Tumor biology
PublicationTitleAbbrev Tumor Biol
PublicationTitleAlternate Tumour Biol
PublicationYear 2016
Publisher Springer Netherlands
Springer Nature B.V
Publisher_xml – name: Springer Netherlands
– name: Springer Nature B.V
References Yang, Jiang, Zhuang, Geng, Hou, Huang (CR14) 2015; 34
Xiong, Yu, Wei, Fu, Cai, Huang (CR18) 2010; 277
Yang, Lv, Liu, Li, Shi, Tang (CR23) 2015; 52
Maiese (CR16) 2015; 1
Dan, Jian, Na, Xiaozhong (CR20) 2012; 5
Kessenbrock, Plaks, Werb (CR22) 2010; 141
Sanei, Chen (CR8) 2015; 27
Jemal, Siegel, Xu (CR1) 2010; 60
Shuang, Wang, Zhou, Shi (CR17) 2015; 32
Kagiya (CR7) 2015; 4
Zhou, Zhou, Zhang, Hu, Wei, Peng (CR15) 2015; 5
García, Vizoso, Andicoechea, Fernandez, Suarez, García-Muñz (CR19) 2000; 15
Luna-Aguirre, de la Luz, Mar-Aguilar, Garza-Veloz, Treviño-Alvarado, Rojas-Martinez (CR9) 2015; 15
CR2
Lim, Lau, Garrett-Engele, Grimson, Schelter, Castle (CR12) 2005; 433
CR3
Sampson, Yoo, Kumar, Vetter, Kolb (CR10) 2015; 3
CR25
Altieri, Fontanella, Agnoletti, Panciani, Spena, Crobeddu (CR5) 2014; 12
Lv, Yang, Lv, Wang, Fan, Shi (CR4) 2015; 52
Kumar, Koul, Petersen, Khandrika, Hwa, Meacham (CR24) 2010; 70
CR21
Lu, You, Yuan, Yang, Samuel, Marcano (CR13) 2015; 16
Kanda, Kodera (CR11) 2015; 21
De Paepe, Vandeneede, Strens, Specenier (CR6) 2015; 18
Q Yang (4575_CR14) 2015; 34
M Sanei (4575_CR8) 2015; 27
W Lu (4575_CR13) 2015; 16
A Paepe De (4575_CR6) 2015; 18
4575_CR21
T Shuang (4575_CR17) 2015; 32
T Kagiya (4575_CR7) 2015; 4
CM Luna-Aguirre (4575_CR9) 2015; 15
A Jemal (4575_CR1) 2010; 60
4575_CR25
R Altieri (4575_CR5) 2014; 12
LP Lim (4575_CR12) 2005; 433
4575_CR2
4575_CR3
Y Zhou (4575_CR15) 2015; 5
I García (4575_CR19) 2000; 15
X Yang (4575_CR23) 2015; 52
K Kessenbrock (4575_CR22) 2010; 141
L Dan (4575_CR20) 2012; 5
VB Sampson (4575_CR10) 2015; 3
M Kanda (4575_CR11) 2015; 21
J Xiong (4575_CR18) 2010; 277
B Lv (4575_CR4) 2015; 52
K Maiese (4575_CR16) 2015; 1
B Kumar (4575_CR24) 2010; 70
26558632 - Mol Neurobiol. 2016 Nov;53(9):6209-6217
20068172 - Cancer Res. 2010 Jan 15;70(2):832-41
20371345 - Cell. 2010 Apr 2;141(1):52-67
26343739 - J Clin Med. 2015 Aug 28;4(9):1741-52
26379391 - World J Gastroenterol. 2015 Sep 14;21(34):9838-52
26532520 - Value Health. 2015 Nov;18(7):A448
23109808 - Onco Targets Ther. 2012;5:271-7
20180843 - FEBS J. 2010 Apr;277(7):1684-94
26380245 - Front Pediatr. 2015 Aug 24;3:69
26342825 - Curr Opin Plant Biol. 2015 Oct;27:199-206
25421212 - Mol Neurobiol. 2016 Jan;53(1):210-215
26406572 - Cancer Biomark. 2015;15(3):299-310
11012099 - Int J Biol Markers. 2000 Jul-Sep;15(3):231-4
20610543 - CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
26568817 - Cell Biosci. 2015 Nov 12;5:61
26239725 - Oncol Rep. 2015 Oct;34(4):1771-8
26179613 - Mol Neurobiol. 2016 Aug;53(6):3948-3953
15685193 - Nature. 2005 Feb 17;433(7027):769-73
26561536 - J Transl Sci. 2015 Nov;1(3):55-57
26520143 - Med Oncol. 2015 Dec;32(12):260
25326893 - Mol Neurobiol. 2015 Dec;52(3):1263-1268
26437241 - Nat Immunol. 2015 Nov;16(11):1185-94
25108671 - Mol Neurobiol. 2015 Aug;52(1):38-44
26535188 - Transl Med UniSa. 2014 Sep 01;12:54-9
28477142 - Mol Neurobiol. 2017 Nov;54(9):7551
References_xml – volume: 141
  start-page: 52
  issue: 1
  year: 2010
  end-page: 67
  ident: CR22
  article-title: Matrix metalloproteinases: regulators of the tumor microenvironment
  publication-title: Cell
  doi: 10.1016/j.cell.2010.03.015
– volume: 15
  start-page: 299
  issue: 3
  year: 2015
  end-page: 310
  ident: CR9
  article-title: Circulating microRNA expression profile in B-cell acute lymphoblastic leukemia
  publication-title: Cancer Biomark
  doi: 10.3233/CBM-150465
– ident: CR2
– volume: 21
  start-page: 9838
  issue: 34
  year: 2015
  end-page: 52
  ident: CR11
  article-title: Recent advances in the molecular diagnostics of gastric cancer
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v21.i34.9838
– volume: 70
  start-page: 832
  issue: 2
  year: 2010
  end-page: 41
  ident: CR24
  article-title: p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-09-2918
– volume: 1
  start-page: 55
  issue: 3
  year: 2015
  end-page: 7
  ident: CR16
  article-title: MicroRNAs and SIRT1: a strategy for stem cell renewal and clinical development?
  publication-title: J Transl Sci
– volume: 12
  start-page: 54
  year: 2014
  end-page: 9
  ident: CR5
  article-title: Role of nitric oxide in glioblastoma therapy: another step to resolve the terrible puzzle?
  publication-title: Transl Med UniSa
– volume: 277
  start-page: 1684
  year: 2010
  end-page: 94
  ident: CR18
  article-title: An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples
  publication-title: FEBS J
  doi: 10.1111/j.1742-4658.2010.07594.x
– volume: 3
  start-page: 69
  year: 2015
  ident: CR10
  article-title: MicroRNAs and potential targets in osteosarcoma: review
  publication-title: Front Pediatr
  doi: 10.3389/fped.2015.00069
– volume: 15
  start-page: 231
  issue: 3
  year: 2000
  end-page: 4
  ident: CR19
  article-title: C-erbB-2 oncoprotein content in gastric cancer and in adjacent mucosa
  publication-title: Int J Biol Markers
– volume: 52
  start-page: 38
  issue: 1
  year: 2015
  end-page: 44
  ident: CR23
  article-title: The clinical utility of matrix metalloproteinase 9 in evaluating pathological grade and prognosis of glioma patients: a meta-analysis
  publication-title: Mol Neurobiol
  doi: 10.1007/s12035-014-8850-2
– volume: 4
  start-page: 1741
  issue: 9
  year: 2015
  end-page: 52
  ident: CR7
  article-title: MicroRNAs and osteolytic bone metastasis: the roles of microRNAs in tumor-induced osteoclast differentiation
  publication-title: J Clin Med
  doi: 10.3390/jcm4091741
– ident: CR25
– volume: 433
  start-page: 769
  issue: 7027
  year: 2005
  end-page: 73
  ident: CR12
  article-title: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
  publication-title: Nature
  doi: 10.1038/nature03315
– volume: 32
  start-page: 260
  issue: 12
  year: 2015
  ident: CR17
  article-title: Over-expression of Sirt1 contributes to chemoresistance and indicates poor prognosis in serous epithelial ovarian cancer (EOC)
  publication-title: Med Oncol
  doi: 10.1007/s12032-015-0706-8
– ident: CR21
– volume: 27
  start-page: 199
  year: 2015
  end-page: 206
  ident: CR8
  article-title: Mechanisms of microRNA turnover
  publication-title: Curr Opin Plant Biol
  doi: 10.1016/j.pbi.2015.07.008
– ident: CR3
– volume: 16
  start-page: 1185
  issue: 11
  year: 2015
  end-page: 94
  ident: CR13
  article-title: The microRNA miR-22 inhibits the histone deacetylase HDAC4 to promote TH17 cell-dependent emphysema
  publication-title: Nat Immunol
  doi: 10.1038/ni.3292
– volume: 60
  start-page: 277
  year: 2010
  end-page: 300
  ident: CR1
  article-title: Cancer statistics, 2010
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.20073
– volume: 5
  start-page: 271
  year: 2012
  end-page: 7
  ident: CR20
  article-title: Crosstalk between EGFR and integrin affects invasion and proliferation of gastric cancer cell line, SGC7901
  publication-title: Onco Targets Ther
– volume: 18
  start-page: A448
  issue: 7
  year: 2015
  ident: CR6
  article-title: The economics of the treatment and follow-up of patients with glioblastoma
  publication-title: Value Health
  doi: 10.1016/j.jval.2015.09.1122
– volume: 52
  start-page: 1263
  issue: 3
  year: 2015
  end-page: 8
  ident: CR4
  article-title: CXCR4 signaling induced epithelial-mesenchymal transition by PI3K/AKT and ERK pathways in glioblastoma
  publication-title: Mol Neurobiol
  doi: 10.1007/s12035-014-8935-y
– volume: 34
  start-page: 1771
  issue: 4
  year: 2015
  end-page: 8
  ident: CR14
  article-title: MicroRNA-22 downregulation of galectin-9 influences lymphocyte apoptosis and tumor cell proliferation in liver cancer
  publication-title: Oncol Rep
– volume: 5
  start-page: 61
  year: 2015
  ident: CR15
  article-title: SIRT1 inhibits adipogenesis and promotes myogenic differentiation in C3H10T1/2 pluripotent cells by regulating Wnt signaling
  publication-title: Cell Biosci
  doi: 10.1186/s13578-015-0055-5
– volume: 21
  start-page: 9838
  issue: 34
  year: 2015
  ident: 4575_CR11
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v21.i34.9838
– volume: 32
  start-page: 260
  issue: 12
  year: 2015
  ident: 4575_CR17
  publication-title: Med Oncol
  doi: 10.1007/s12032-015-0706-8
– ident: 4575_CR25
  doi: 10.1007/s12035-015-9340-x
– volume: 3
  start-page: 69
  year: 2015
  ident: 4575_CR10
  publication-title: Front Pediatr
  doi: 10.3389/fped.2015.00069
– volume: 18
  start-page: A448
  issue: 7
  year: 2015
  ident: 4575_CR6
  publication-title: Value Health
  doi: 10.1016/j.jval.2015.09.1122
– volume: 34
  start-page: 1771
  issue: 4
  year: 2015
  ident: 4575_CR14
  publication-title: Oncol Rep
  doi: 10.3892/or.2015.4167
– ident: 4575_CR21
  doi: 10.1007/s12035-015-9121-6
– ident: 4575_CR3
  doi: 10.1007/s12035-015-9525-3
– volume: 5
  start-page: 61
  year: 2015
  ident: 4575_CR15
  publication-title: Cell Biosci
  doi: 10.1186/s13578-015-0055-5
– volume: 4
  start-page: 1741
  issue: 9
  year: 2015
  ident: 4575_CR7
  publication-title: J Clin Med
  doi: 10.3390/jcm4091741
– volume: 60
  start-page: 277
  year: 2010
  ident: 4575_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.20073
– volume: 15
  start-page: 231
  issue: 3
  year: 2000
  ident: 4575_CR19
  publication-title: Int J Biol Markers
  doi: 10.1177/172460080001500305
– volume: 16
  start-page: 1185
  issue: 11
  year: 2015
  ident: 4575_CR13
  publication-title: Nat Immunol
  doi: 10.1038/ni.3292
– volume: 5
  start-page: 271
  year: 2012
  ident: 4575_CR20
  publication-title: Onco Targets Ther
– volume: 70
  start-page: 832
  issue: 2
  year: 2010
  ident: 4575_CR24
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-09-2918
– volume: 12
  start-page: 54
  year: 2014
  ident: 4575_CR5
  publication-title: Transl Med UniSa
  doi: 10.1186/1479-5876-12-54
– volume: 15
  start-page: 299
  issue: 3
  year: 2015
  ident: 4575_CR9
  publication-title: Cancer Biomark
  doi: 10.3233/CBM-150465
– volume: 141
  start-page: 52
  issue: 1
  year: 2010
  ident: 4575_CR22
  publication-title: Cell
  doi: 10.1016/j.cell.2010.03.015
– volume: 433
  start-page: 769
  issue: 7027
  year: 2005
  ident: 4575_CR12
  publication-title: Nature
  doi: 10.1038/nature03315
– volume: 1
  start-page: 55
  issue: 3
  year: 2015
  ident: 4575_CR16
  publication-title: J Transl Sci
– volume: 277
  start-page: 1684
  year: 2010
  ident: 4575_CR18
  publication-title: FEBS J
  doi: 10.1111/j.1742-4658.2010.07594.x
– volume: 27
  start-page: 199
  year: 2015
  ident: 4575_CR8
  publication-title: Curr Opin Plant Biol
  doi: 10.1016/j.pbi.2015.07.008
– volume: 52
  start-page: 38
  issue: 1
  year: 2015
  ident: 4575_CR23
  publication-title: Mol Neurobiol
  doi: 10.1007/s12035-014-8850-2
– volume: 52
  start-page: 1263
  issue: 3
  year: 2015
  ident: 4575_CR4
  publication-title: Mol Neurobiol
  doi: 10.1007/s12035-014-8935-y
– ident: 4575_CR2
  doi: 10.1007/s12035-014-9006-0
– reference: 20371345 - Cell. 2010 Apr 2;141(1):52-67
– reference: 26343739 - J Clin Med. 2015 Aug 28;4(9):1741-52
– reference: 28477142 - Mol Neurobiol. 2017 Nov;54(9):7551
– reference: 26379391 - World J Gastroenterol. 2015 Sep 14;21(34):9838-52
– reference: 11012099 - Int J Biol Markers. 2000 Jul-Sep;15(3):231-4
– reference: 26406572 - Cancer Biomark. 2015;15(3):299-310
– reference: 20068172 - Cancer Res. 2010 Jan 15;70(2):832-41
– reference: 26561536 - J Transl Sci. 2015 Nov;1(3):55-57
– reference: 26437241 - Nat Immunol. 2015 Nov;16(11):1185-94
– reference: 26532520 - Value Health. 2015 Nov;18(7):A448
– reference: 20180843 - FEBS J. 2010 Apr;277(7):1684-94
– reference: 20610543 - CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
– reference: 26568817 - Cell Biosci. 2015 Nov 12;5:61
– reference: 25421212 - Mol Neurobiol. 2016 Jan;53(1):210-215
– reference: 25326893 - Mol Neurobiol. 2015 Dec;52(3):1263-1268
– reference: 26380245 - Front Pediatr. 2015 Aug 24;3:69
– reference: 26342825 - Curr Opin Plant Biol. 2015 Oct;27:199-206
– reference: 26520143 - Med Oncol. 2015 Dec;32(12):260
– reference: 23109808 - Onco Targets Ther. 2012;5:271-7
– reference: 25108671 - Mol Neurobiol. 2015 Aug;52(1):38-44
– reference: 15685193 - Nature. 2005 Feb 17;433(7027):769-73
– reference: 26535188 - Transl Med UniSa. 2014 Sep 01;12:54-9
– reference: 26179613 - Mol Neurobiol. 2016 Aug;53(6):3948-3953
– reference: 26558632 - Mol Neurobiol. 2016 Nov;53(9):6209-6217
– reference: 26239725 - Oncol Rep. 2015 Oct;34(4):1771-8
SSID ssj0015996
Score 2.35112
Snippet Recently, microRNAs (miRNAs), a kind of small and non-coding RNA, can target the downstream molecules. Increasing evidence demonstrates that miRNAs meditate...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 6761
SubjectTerms 3' Untranslated Regions
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Cell growth
Cell Line, Tumor
Cell Movement
Cell Proliferation
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Glioblastoma - genetics
Glioblastoma - mortality
Glioblastoma - pathology
Humans
MicroRNAs
MicroRNAs - chemistry
MicroRNAs - genetics
Nervous system
Original Article
RNA Interference
RNA, Messenger - chemistry
RNA, Messenger - genetics
Sirtuin 1 - chemistry
Sirtuin 1 - genetics
Transcriptome
Title miR-22 inhibits the proliferation, motility, and invasion of human glioblastoma cells by directly targeting SIRT1
URI https://link.springer.com/article/10.1007/s13277-015-4575-8
https://www.ncbi.nlm.nih.gov/pubmed/26662303
https://www.proquest.com/docview/1790153929
https://www.proquest.com/docview/1790468286
Volume 37
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwEB61i9T2gih9pTxkpJ4olpLYyZrjglhoKzgAK9FTZDs2jbQkwGYr8e-ZyWMpolTqKQdPnMif7fk8M54B-BKSHdAIyXMVGzygRDk30lhOJoahkXJXuybK9yQ9msjvF8lFd4971ke79y7JZqd-uOwmyN2I6otL5BhcvYSlhI7uOIkn8WjhOqB8I42LEzcYyibWuzL_1sVjZfSEYT7xjjZKZ7wCyx1bZKMW3rfwwpWr8Hq_L9K2Cq-OO9_4O7i5Kk55HLOi_FWYop4xpHbsmoryeNfCvMMo8o549w7TZY6SvzUZy1jlWVOrj11Oi8ogn66rK83Ipj9j5o61am96x9qwcfxTdvbt9Dx6D5Pxwfn-Ee8KKnArhaq5VjYRRno8xFjUy17kuLyJUnid7EZxJK2KsVFLIdLcRKlV3scudNq7XGvrxAcYlFXpPgGT1gzt0Bgz1KHUCptTo1Mf5UkSq1zoAMJ-ZDPbZRunohfT7CFPMoGRIRgZgZGpALYXr1y3qTb-Jbzew5V1q26WUbYx3MGR8QWwtWhGRGjAdOmqeSsjU7o8H8DHFubF15CsIBsMRQBfe9z_6Py5X_n8X9Jr8AY5V9rGTK7DoL6duw3kNbXZhKXReG_vhJ6HP38cbDbz-h7qBfFe
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED9BkRgvE4yvjI55Ek8wS0nspN7jVDF1sO1ha6W9RbZjQ6QuKTRF6n_PXT66TQMknn1xLP9s38935zuADyHZAY2QPFexwQtKlHMjjeVkYhgZKY-0a6J8L9LJTH65Tq67d9zLPtq9d0k2J_XtYzdB7kZUX1wix-DqMTxBLqAojmsWH29cB5RvpHFx4gFD2cR6V-afurivjB4wzAfe0UbpnDyH7Y4tsuMW3hfwyJU7sDXui7TtwNPzzjf-En7cFJc8jllRfi9MUS8ZUju2oKI83rUwHzKKvCPefch0maPkL03GMlZ51tTqY9_mRWWQT9fVjWZk018ys2at2puvWRs2jiNlV6eX0-gVzE4-T8cT3hVU4FYKVXOtbCKM9HiJsaiXvchxexOl8Do5iuJIWhVjo5ZCpLmJUqu8j13otHe51taJ1zAoq9K9BSatGdmRMWakQ6kVNqdGpz7KkyRWudABhP3MZrbLNk5FL-bZbZ5kAiNDMDICI1MBfNx8smhTbfxLeNjDlXW7bplRtjE8wZHxBXCwaUZEaMJ06apVKyNTejwfwJsW5s3fkKwgGwxFAJ963O90_reh7P6X9D5sTabnZ9nZ6cXXd_AM-Vfaxk8OYVD_XLk95Di1ed-s6d9SIfFB
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BkUovCMorUMBInKBWk9jJuseqsGp5VKh0pd4iPyHSNtmyKVL_PTNxsgUVkDh74lj-bM_nmfEMwKuU7IBGSO5UbvCCkjlupLGcTAwTI-Wu9n2U71F5MJPvT4vToc7pcox2H12S8U0DZWlqup2FCztXD98EuR5RlXGJfIOrm3ALT-OMlvUs31u5ESj3SO_uxMOGMouNbs0_dfG7YrrGNq95SnsFNL0LdwbmyPYi1Pfghm824fb-WLBtE9Y_DX7y-3B-Vh_zPGd18602dbdkSPPYggr0BB8h32YUhUccfJvpxqHkD02GM9YG1tftY1_ndWuQW3ftmWZk318yc8miCpxfshhCjiNlXw6PT7IHMJu-O9k_4ENxBW6lUB3XyhbCyIAXGos6OgiHW53oRdDFbpZn0qocG7UUonQmK60KIfep18E7ra0XD2GtaRv_GJi0ZmInxpiJTqVW2FwaXYbMFUWunNAJpOPMVnbIPE4FMObVVc5kAqNCMCoCo1IJvF59sohpN_4lvDXCVQ07cFlR5jE8zZH9JfBy1YyI0ITpxrcXUUaW9JA-gUcR5tXfkLggM0xFAm9G3H_p_G9DefJf0i9g_fPbafXx8OjDU9hAKlbGUMotWOu-X_hnSHc687xf0j8BNoX1fQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=miR-22+inhibits+the+proliferation%2C+motility%2C+and+invasion+of+human+glioblastoma+cells+by+directly+targeting+SIRT1&rft.jtitle=Tumor+biology&rft.au=Chen%2C+Hanchun&rft.au=Lu%2C+Qiong&rft.au=Fei%2C+Xifeng&rft.au=Shen%2C+Likui&rft.date=2016-05-01&rft.issn=1010-4283&rft.eissn=1423-0380&rft.volume=37&rft.issue=5&rft.spage=6761&rft.epage=6768&rft_id=info:doi/10.1007%2Fs13277-015-4575-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s13277_015_4575_8
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1010-4283&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1010-4283&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1010-4283&client=summon